GLTO Research and Charts

GLTO - Galecto Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10)

Last 21.52	Change ⇓ -2.48 (-10.33%)	Volume 57,185
	Open 23.67	High 23.83	Low 21.50

8EMA (Daily) 24.00	40EMA (Daily) 24.01	50EMA (Daily) 23.29	STO (Daily) 15.929	MACD Hist (Daily) -0.487
8EMA (Weekly) 23.973	40EMA (Weekly) 15.23	50EMA (Weekly) 14.15	STO (Weekly) 54.984	MACD Hist (Weekly) -1.132


Company Profile
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.